Lipocine Capital Expenditures vs Depreciation Analysis

LPCN Stock

USD 4.45 0.03 0.68%

Lipocine financial indicator trend analysis is infinitely more than just investigating Lipocine recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lipocine is a good investment. Please check the relationship between Lipocine Capital Expenditures and its Depreciation accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Capital Expenditures vs Depreciation

Capital Expenditures vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lipocine Capital Expenditures account and Depreciation. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Lipocine's Capital Expenditures and Depreciation is -0.02. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Depreciation in the same time period over historical financial statements of Lipocine, assuming nothing else is changed. The correlation between historical values of Lipocine's Capital Expenditures and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Lipocine are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Capital Expenditures i.e., Lipocine's Capital Expenditures and Depreciation go up and down completely randomly.

Correlation Coefficient

-0.02

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Lipocine to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Lipocine operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Depreciation

Depreciation indicates how much of Lipocine value has been used up. For tax purposes Lipocine can deduct the cost of the tangible assets it purchases as business expenses. However, Lipocine must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most indicators from Lipocine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lipocine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.As of the 28th of November 2024, Selling General Administrative is likely to grow to about 5.8 M, while Tax Provision is likely to drop 411.40.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	16.6M	11.8M	15.1M	9.3M
Cost Of Revenue	7.7M	8.6M	10.2M	9.4M

Total Operating Expenses Cost Of Revenue

Lipocine fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Debt	Retained Earnings	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Retained Earnings Total Equity	Short Term Investments	Capital Surpluse	Treasury Stock	Property Plant And Equipment Net	Non Current Assets Total
Total Assets		0.4	0.44	0.96	-0.28	-0.5	-0.54	0.54	0.51	0.4	0.99	0.43	0.52	0.12	0.69	0.2	1.0	0.46	-0.08	0.91	-0.58	0.66	0.66	-0.54	0.21	0.54
Other Current Liab	0.4		0.63	0.35	-0.07	0.0	-0.36	0.19	-0.04	0.07	0.38	0.15	0.21	-0.02	0.4	0.21	0.41	0.16	0.11	0.33	-0.39	0.47	0.39	-0.53	0.28	0.12
Total Current Liabilities	0.44	0.63		0.22	-0.23	0.1	-0.7	0.72	0.04	0.14	0.33	0.42	0.41	0.57	0.69	0.85	0.44	0.45	-0.46	0.2	-0.77	0.34	0.66	-0.71	-0.26	0.22
Total Stockholder Equity	0.96	0.35	0.22		-0.26	-0.56	-0.39	0.38	0.52	0.41	0.99	0.36	0.46	-0.06	0.56	-0.07	0.96	0.39	0.08	0.95	-0.41	0.65	0.54	-0.39	0.34	0.54
Other Liab	-0.28	-0.07	-0.23	-0.26		-0.14	0.61	-0.47	0.13	-0.69	-0.23	-0.77	-0.75	-0.22	-0.55	-0.09	-0.25	-0.77	-0.17	-0.36	0.55	-0.38	-0.56	0.32	-0.24	-0.37
Net Debt	-0.5	0.0	0.1	-0.56	-0.14		-0.18	-0.17	-0.97	0.25	-0.58	0.2	0.19	0.08	0.03	0.21	-0.55	0.2	0.13	-0.51	-0.17	0.25	0.04	-0.12	-0.02	0.2
Retained Earnings	-0.54	-0.36	-0.7	-0.39	0.61	-0.18		-0.76	0.07	-0.66	-0.45	-0.87	-0.86	-0.44	-0.95	-0.59	-0.52	-0.88	-0.08	-0.49	0.99	-0.58	-0.95	0.82	-0.27	-0.36
Accounts Payable	0.54	0.19	0.72	0.38	-0.47	-0.17	-0.76		0.29	0.42	0.46	0.68	0.63	0.51	0.79	0.63	0.54	0.7	-0.38	0.48	-0.76	0.25	0.79	-0.48	-0.18	0.26
Cash	0.51	-0.04	0.04	0.52	0.13	-0.97	0.07	0.29		-0.27	0.57	-0.16	-0.16	0.12	0.05	0.01	0.57	-0.16	-0.28	0.45	0.05	-0.3	0.03	0.03	-0.12	-0.22
Other Assets	0.4	0.07	0.14	0.41	-0.69	0.25	-0.66	0.42	-0.27		0.36	0.9	0.91	-0.02	0.6	-0.01	0.35	0.88	0.39	0.55	-0.58	0.66	0.62	-0.32	0.35	0.63
Cash And Short Term Investments	0.99	0.38	0.33	0.99	-0.23	-0.58	-0.45	0.46	0.57	0.36		0.36	0.46	0.02	0.61	0.07	0.99	0.39	0.0	0.94	-0.47	0.62	0.59	-0.47	0.27	0.48
Common Stock Total Equity	0.43	0.15	0.42	0.36	-0.77	0.2	-0.87	0.68	-0.16	0.9	0.36		0.98	0.27	0.79	0.28	0.4	1.0	0.25	0.5	-0.81	0.55	0.8	-0.53	0.27	0.48
Common Stock Shares Outstanding	0.52	0.21	0.41	0.46	-0.75	0.19	-0.86	0.63	-0.16	0.91	0.46	0.98		0.23	0.81	0.23	0.48	0.98	0.29	0.59	-0.81	0.67	0.82	-0.58	0.34	0.56
Other Current Assets	0.12	-0.02	0.57	-0.06	-0.22	0.08	-0.44	0.51	0.12	-0.02	0.02	0.27	0.23		0.4	0.66	0.13	0.3	-0.46	-0.07	-0.49	-0.09	0.38	-0.36	-0.38	0.0
Other Stockholder Equity	0.69	0.4	0.69	0.56	-0.55	0.03	-0.95	0.79	0.05	0.6	0.61	0.79	0.81	0.4		0.53	0.68	0.81	0.01	0.64	-0.96	0.66	1.0	-0.83	0.3	0.47
Total Liab	0.2	0.21	0.85	-0.07	-0.09	0.21	-0.59	0.63	0.01	-0.01	0.07	0.28	0.23	0.66	0.53		0.2	0.31	-0.61	-0.1	-0.67	0.07	0.5	-0.59	-0.46	0.05
Total Current Assets	1.0	0.41	0.44	0.96	-0.25	-0.55	-0.52	0.54	0.57	0.35	0.99	0.4	0.48	0.13	0.68	0.2		0.43	-0.08	0.9	-0.56	0.61	0.65	-0.54	0.21	0.47
Common Stock	0.46	0.16	0.45	0.39	-0.77	0.2	-0.88	0.7	-0.16	0.88	0.39	1.0	0.98	0.3	0.81	0.31	0.43		0.2	0.51	-0.83	0.58	0.82	-0.55	0.24	0.53
Property Plant Equipment	-0.08	0.11	-0.46	0.08	-0.17	0.13	-0.08	-0.38	-0.28	0.39	0.0	0.25	0.29	-0.46	0.01	-0.61	-0.08	0.2		0.2	0.02	0.25	0.04	-0.06	0.87	-0.1
Net Tangible Assets	0.91	0.33	0.2	0.95	-0.36	-0.51	-0.49	0.48	0.45	0.55	0.94	0.5	0.59	-0.07	0.64	-0.1	0.9	0.51	0.2		-0.46	0.66	0.65	-0.41	0.45	0.48
Retained Earnings Total Equity	-0.58	-0.39	-0.77	-0.41	0.55	-0.17	0.99	-0.76	0.05	-0.58	-0.47	-0.81	-0.81	-0.49	-0.96	-0.67	-0.56	-0.83	0.02	-0.46		-0.59	-0.94	0.86	-0.19	-0.4
Short Term Investments	0.66	0.47	0.34	0.65	-0.38	0.25	-0.58	0.25	-0.3	0.66	0.62	0.55	0.67	-0.09	0.66	0.07	0.61	0.58	0.25	0.66	-0.59		0.65	-0.56	0.43	0.77
Capital Surpluse	0.66	0.39	0.66	0.54	-0.56	0.04	-0.95	0.79	0.03	0.62	0.59	0.8	0.82	0.38	1.0	0.5	0.65	0.82	0.04	0.65	-0.94	0.65		-0.81	0.33	0.45
Treasury Stock	-0.54	-0.53	-0.71	-0.39	0.32	-0.12	0.82	-0.48	0.03	-0.32	-0.47	-0.53	-0.58	-0.36	-0.83	-0.59	-0.54	-0.55	-0.06	-0.41	0.86	-0.56	-0.81		-0.32	-0.25
Property Plant And Equipment Net	0.21	0.28	-0.26	0.34	-0.24	-0.02	-0.27	-0.18	-0.12	0.35	0.27	0.27	0.34	-0.38	0.3	-0.46	0.21	0.24	0.87	0.45	-0.19	0.43	0.33	-0.32		0.02
Non Current Assets Total	0.54	0.12	0.22	0.54	-0.37	0.2	-0.36	0.26	-0.22	0.63	0.48	0.48	0.56	0.0	0.47	0.05	0.47	0.53	-0.1	0.48	-0.4	0.77	0.45	-0.25	0.02

Click cells to compare fundamentals

Lipocine Account Relationship Matchups

Lipocine fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	19.7M	25.4M	52.5M	37.5M	23.0M	29.7M
Other Current Liab	449.3K	1.7M	2.0M	1.1M	1.2M	1.5M
Total Current Liabilities	5.0M	6.6M	5.6M	1.7M	2.6M	3.4M
Total Stockholder Equity	6.3M	15.3M	45.6M	35.6M	20.4M	24.6M
Net Debt	(2.6M)	(13.6M)	(639.7K)	(3.1M)	(4.8M)	(5.0M)
Retained Earnings	(151.1M)	(172.0M)	(172.7M)	(183.4M)	(199.8M)	(189.8M)
Accounts Payable	1.2M	1.6M	1.3M	600.4K	1.4M	798.8K
Cash	9.7M	19.2M	3.0M	3.1M	4.8M	9.2M
Cash And Short Term Investments	14.1M	19.7M	44.6M	32.5M	22.0M	26.6M
Common Stock Total Equity	2.2K	3.8K	7.0K	8.8K	10.2K	10.7K
Common Stock Shares Outstanding	1.5M	3.3M	5.2M	5.3M	5.3M	5.5M
Liabilities And Stockholders Equity	19.7M	25.4M	52.5M	37.5M	23.0M	29.7M
Other Current Assets	545.9K	5.7M	1.5M	945.3K	773.4K	1.5M
Other Stockholder Equity	157.4M	187.4M	218.2M	219.1M	220.1M	147.6M
Total Liab	13.4M	10.0M	6.9M	1.9M	2.6M	5.1M
Total Current Assets	19.6M	25.3M	46.4M	34.1M	22.9M	28.8M
Common Stock	3.8K	7.0K	8.8K	8.9K	8.9K	9.3K
Property Plant Equipment	19.0K	3.6K	7.2K	131.6K	118.4K	124.4K
Net Tangible Assets	6.3M	15.3M	45.6M	35.6M	41.0M	27.0M
Retained Earnings Total Equity	(138.1M)	(151.1M)	(172.0M)	(172.7M)	(155.4M)	(163.2M)
Short Term Investments	4.3M	450.0K	41.7M	29.4M	17.3M	15.1M
Capital Surpluse	147.5M	157.4M	187.4M	218.3M	251.0M	143.4M
Property Plant And Equipment Net	3.6K	0.0	7.2K	131.6K	116.1K	63.4K
Non Current Assets Total	27.3K	23.8K	6.1M	3.4M	139.8K	132.9K
Property Plant And Equipment Gross	3.6K	1.1M	1.2M	1.3M	1.3M	1.4M
Net Receivables	16.5K	391.0	247.3K	659.9K	52.3K	49.6K
Net Invested Capital	13.4M	20.9M	47.9M	35.6M	20.4M	27.8M
Net Working Capital	14.7M	18.7M	40.8M	32.5M	20.2M	25.5M
Short Long Term Debt Total	7.1M	5.6M	2.3M	17.2K	15.4K	14.7K
Capital Stock	3.8K	7.0K	8.8K	8.9K	8.9K	7.2K

Pair Trading with Lipocine

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipocine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will appreciate offsetting losses from the drop in the long position's value.

Moving against Lipocine Stock

0.74	FDMT	4D Molecular Therapeutics	Pair Corr
0.65	INKT	Mink Therapeutics	Pair Corr
0.63	NKTX	Nkarta Inc Buyout Trend	Pair Corr
0.62	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.6	RGNX	Regenxbio	Pair Corr

The ability to find closely correlated positions to Lipocine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipocine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipocine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipocine to buy it.

The correlation of Lipocine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipocine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipocine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Lipocine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:

How To Invest In Lipocine

Details

Is Lipocine Stock a good investment?

Details

What is Lipocine's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.75)

Revenue Per Share

0.903

Quarterly Revenue Growth

137.519

Return On Assets

(0.23)

Return On Equity

(0.34)

The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lipocine Capital Expenditures vs Depreciation Analysis

Capital Expenditures vs Depreciation

Capital Expenditures vs Depreciation Correlation Analysis

Correlation Coefficient

Capital Expenditures

Depreciation

Lipocine fundamental ratios Correlations

Lipocine Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lipocine fundamental ratios Accounts

Pair Trading with Lipocine

Moving against Lipocine Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Common Stock	+ 1.0	Common Stock Total Equity
Capital Surpluse	+ 1.0	Other Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Retained Earnings Total Equity	+ 0.99	Retained Earnings

Cash	- 0.97	Net Debt
Retained Earnings Total Equity	- 0.96	Other Stockholder Equity
Capital Surpluse	- 0.95	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Capital Surpluse	- 0.94	Retained Earnings Total Equity
Common Stock	- 0.88	Retained Earnings